GlassScriptPhysician profile
Katasha Flatt
NPI 1588010185
$7,814.35
in general payments reported to CMS, 2019-2025
28 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $69.00 · 2023: $2,128 · 2024: $2,470 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,292.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,627.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,034.43 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $851.85 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $573.73 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $380.69 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $278.38 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $230.24 | 2023-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $209.59 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $175.76 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $142.88 | 2023 | Ocaliva |
| Pharmacosmos Therapeutics INC. | $133.57 | 2021-2023 | Monoferric |
| Lilly USA, LLC | $125.60 | 2024-2025 | Omvoh |
| Pfizer INC. | $120.43 | 2021-2025 | |
| Genzyme Corporation | $116.55 | 2023-2025 | |
| Gilead Sciences, INC. | $113.42 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $102.05 | 2025 | Rezdiffra |
| Novo Nordisk INC | $101.05 | 2023-2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $73.40 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $73.20 | 2021-2023 | Dificid |
| Daiichi Sankyo INC. | $68.54 | 2023-2025 | Injectafer |
| Nestle Healthcare Nutrition INC. | $61.79 | 2021-2023 | |
| Organon LLC | $54.07 | 2023-2024 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $34.66 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $34.24 | 2023-2024 | Idacio |
| Redhill Biopharma INC. | $31.04 | 2021 | |
| Ironwood Pharmaceuticals, INC | $29.53 | 2024 | |
| Braintree Laboratories, INC. | $20.77 | 2023 | Sutab, Suflave |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katasha Flatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.